The Thailand Food and Drug Administration approved Antengene's (HKG:6996) new drug application for its selinexor drug, according to a Monday filing with the Hong Kong Stock Exchange.
The approvals are for the combination of selinexor with bortezomib and dexamethasone for multiple myeloma patients with at least one prior therapy.
The drug is also indicated for combination with dexamethasone for multiple myeloma patients with at least four prior therapies and resistance to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, the filing said.
Shares closed 4% higher during Monday's trading.
Price (HKD): $0.57, Change: $+0.020, Percent Change: +3.64%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。